Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian market down 1%, Japan tanks 3%
Fri, 8 Aug 09:30 am

Barring China (up 0.3%), all major Asian stock markets have opened the day in the red yet again with stock markets in Japan (down 3%) and South Korea (down 1 %) leading the pack of losers. The Indian share markets have also opened the day on a negative note. All sectoral indices have opened in the red with realty and power indices leading the losses.

The Sensex today is down by around 253 points (1%), while the NSE-Nifty is down by about 74 points (1%). Mid and small cap stocks are also trading in the red with the BSE Mid Cap and BSE Small Cap indices down by around 1.2% and 1.4% respectively. The rupee is currently trading at Rs 61.68 to the US dollar.

FMCG stocks have opened the day on a weak note with Archies Ltd and Lakshmi Energy leading the losses. FMCG major Nestle India has announced its financial results for the quarter ended June 2014. During the quarter, the company reported 9.3% YoY growth in the topline, with net sales standing at Rs 24,189.1 m. Operating profit remained almost flat at Rs 4,908.6 m during the quarter as higher expenditure led operating margins to contract from 21.9% in 1QFY14 to 20.2% in 1QFY15. Other income rose substantially by 50.1% YoY to Rs 231.2 m. Depreciation and interest expenses declined by 5.1% YoY and 55.7% YoY respectively. At the bottomline level, net profit increased by 6.1% YoY to Rs 2,878.6 m. Net profit margin contracted from 12.2% in 1QFY14 to 11.8% in 1QFY15.

Indian Pharma stocks have opened the day on a weak note with Ipca Laboratories and JB Chemicals leading the losses. Hyderabad-based Aurobindo Pharma has also announced its consolidated financial results for the quarter ended June 2014. During the quarter, the company reported 70.3% YoY growth in the topline, with net sales standing at Rs 28,946.1 m. Operating profit shot up by 386.4% YoY to Rs 6,581.5 m during the quarter as the company had reported forex losses of Rs 1,724.1 m in the quarter ended June 2013. At the bottomline level, net profit increased by 2,272.7% YoY to Rs 4,142.7 m. It must be noted that the company's financials are not comparable with the corresponding quarter of last year as during the recent quarter, Agile Pharma BV-Netherlands, a step-down subsidiary of Aurobindo Pharma, has acquired select European business of Actavis. The financial result for 1QFY15 includes the results of the operation of the above business from April 1, 2014. The stock of Aurobindo Pharma is trading up by around 1.2%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian market down 1%, Japan tanks 3%". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.